Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAT-004
- Development stage
- Preclinical
- Lead developer
- New G Lab Pharma
- Modality
- Small Molecules
01
Overview
KAT-004 is a small molecule anticancer therapeutic being developed by NewG Lab Pharma. It is part of the KoDiscovery Anticancer Therapeutics (KAT) pipeline, which focuses on targeting the Warburg Effect, a metabolic phenomenon where cancer cells preferentially undergo aerobic glycolysis even in the presence of oxygen. By inhibiting this specific metabolic pathway, KAT-004 aims to selectively disrupt the energy production and biosynthetic processes of breast cancer cells. As of the current pipeline status, KAT-004 is in the preclinical stage, with preparations underway for clinical trials in the United States and potentially Australia.
- Other names
- KoDiscovery Anticancer Therapeutics 004
Beyond the preview
Go deeper on KAT-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAT-004.